AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01498822
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
Trial: NCT04678921
Drug: TJ210001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human anti-C5aR monoclonal antibody
Trial: NCT02565277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00881491
Drug: Double Antibiotic Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
Trial: NCT00881491
Drug: Triple Antibiotic Paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
Trial: NCT00352092
Drug: calcineurin inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02913664
Drug: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)
RxNorm normalized name: Angiotensin II receptor blockers (ARBs) and calcium channel blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP\<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.~Intensive Reduction of Vascular Risk Factors (IRVR)
Trial: NCT00242372
Drug: Insulin at least 30 units/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05125575
Drug: Glucophage® XR 1000 mg Prolonged Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of the Reference (R) product was administered orally with 240 mL of water.
Trial: NCT00361439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs in each nostril once daily of nasal spray
Trial: NCT02809105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily
Trial: NCT01684098
Drug: Tc 99m EC20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03204955
Drug: PlasmaLyte
RxNorm normalized name: PLASMALYTE A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
Trial: NCT00910962
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
Trial: NCT00910962
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
Trial: NCT00910962
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02461719
Drug: CYPORIN N EYE DROPS 0.05%(TJCS eye drop)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop twice/day for 12 weeks to both eyes.
Trial: NCT02805426
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05199623
Drug: tailored Guizhi decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored guizhi decoction powder is a compound Chinese herbal medicine which contains 7.0g of guizhi, 1.5g of chuanxiong, 1.5g of zhimu, 1.5g of xinyi, 0.3g of mahuang, 1.0g of baizh, 2.0g of jili, 1.5g of fuling, and 1.0g of danshen.
Trial: NCT03465774
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Receive via IPC
Trial: NCT03595930
Drug: Arnuity
RxNorm normalized name: Arnuity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.
Trial: NCT02836236
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF 25 mg tablet administered orally once daily
Trial: NCT02836236
Drug: TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF placebo tablet administered orally once daily
Trial: NCT00084370
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
Trial: NCT02836236
Drug: TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF placebo tablet administered orally once daily
Trial: NCT01106677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
Trial: NCT01163214
Drug: Nerve Block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
Trial: NCT04849286
Drug: HTL0016878
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution
Trial: NCT00161239
Drug: Doxil, Methotrexate, L-Asparaginase, Prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01119898
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
Trial: NCT03337945
Drug: Basel phenotyping cocktail capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling
Trial: NCT03360916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One matching placebo tablet by mouth every day for 12 weeks.
Trial: NCT02796066
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied once a day
Trial: NCT02796066
Drug: TSN2898
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied once a day
Trial: NCT03397329
Drug: AG-348 Sequence B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Treatment Period 1 Single 50 mg dose of AG-348 administered as a tablet formulation (1 × 50 mg tablet)~2. Washout Period 7 days~3. Treatment Period 2 Single 50 mg dose of AG-348 administered as a capsule formulation (2 × 25 mg capsules)
Trial: NCT01159236
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2 for 4 courses (once every 7 days)
Trial: NCT01159236
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
Trial: NCT01159236
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
Trial: NCT02311413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
Trial: NCT01466569
Drug: AbGn-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
Trial: NCT01466569
Drug: AbGn-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
Trial: NCT02142725
Drug: LT-02
RxNorm normalized name: LT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four times per day
Trial: NCT02142725
Drug: LT-02
RxNorm normalized name: LT KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two times per day
Trial: NCT02142725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four times per day
Trial: NCT00941798
Drug: QMF149 Twisthaler®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily via multi-dose dry-powder inhaler
Trial: NCT01689246
Drug: TRx0237 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRx0237 75 mg tablets will be administered twice daily.
Trial: NCT01689246
Drug: TRx0237 250 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRx0237 125 mg tablets will be administered twice daily.
Trial: NCT01689246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
Trial: NCT03724903
Drug: Corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone(Common brand names: Medrol) or prednisone 20-40mg, qd for two weeks, then temper the dose gradually, and then 20mg qd for maintenance (The total duration of the treatment is 6 months).
Trial: NCT01248052
Drug: LY2979165
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT01248052
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally
Trial: NCT02381132
Drug: Norco 7.5mg/325
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02381132
Drug: MNK155
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01857999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222350
Drug: 75mg DS-8500a tablet
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222350
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03333824
Drug: CYP1A2 (caffeine)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Part A, Period 1, patients will be administered a 3 drug cocktail of caffeine, omeprazole and midazolam on Day -8 followed by a washout period of at least 7 but no more than 14 days. In Part A, Period 2, AZD1775 capsules will be administered orally, 225 mg bid, until steady state for 2.5 days (total of 5 doses) and administered together with the cocktail on the morning of Day 3.
Trial: NCT03834766
Drug: AMPH ER Tab 5, 10, 15 and 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine
Trial: NCT03333824
Drug: Wee-1 kinase inhibitor AZD1775
RxNorm normalized name: PROTEIN KINASE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of 225 mg AZD1775, (3 x 75 mg, printed capsules) administered orally. The drug class of AZD1775 is Wee-1 kinase inhibitor.
Trial: NCT03933618
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00438607
Drug: BIIB014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
Trial: NCT00438607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo for MTD or MTD-1
Trial: NCT01249638
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
Trial: NCT02395133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of Placebo (for Dupilumab) was administered once weekly (QW).
Trial: NCT04444635
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous fentanyl infusion throughout the surgical procedure.
Trial: NCT01249638
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
Trial: NCT02671266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
Trial: NCT02165332
Drug: Part 1: SAD RO7033877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02165332
Drug: Part 1: SAD placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT02165332
Drug: Part 2: Treatment A, RO7033877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose RO7033877 and moxifloxacin placebo
Trial: NCT02165332
Drug: Part 2: Treatment B, RO7033877
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose RO7033877 and moxifloxacin placebo
Trial: NCT02310022
Drug: Drug Omega 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g (4 capsules) once a day, administered with food
Trial: NCT02310022
Drug: Drug Omega-3 Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g (4 capsules) once a day, administered with food
Trial: NCT00110370
Drug: Lispro Mixture Therapy
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01738880
Drug: CVP
RxNorm normalized name: CVP Manometer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
Trial: NCT02822625
Drug: QUTENZA®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01018225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill, once a day, for six weeks
Trial: NCT02484170
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
Trial: NCT01041846
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
Trial: NCT02228239
Drug: Placebo (Matched to Mirtazapine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
Trial: NCT03315130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous (SC) injection
Trial: NCT03133299
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone for four months
Trial: NCT02091596
Drug: PluroGel N
RxNorm normalized name: PLUROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT02091596
Drug: PluroGel
RxNorm normalized name: PLUROGEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PluroGel Vehicle Placebo Comparator
Trial: NCT00681109
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: custom eye drop to be applied three times a day in both eyes for three months
Trial: NCT04432714
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 10 mg/m2/day CI24h d1-d4
Trial: NCT04432714
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m2/day IV d5
Trial: NCT00387140
Drug: MK2295
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01915667
Drug: 200 mg GLPG0634 as capsules, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
Trial: NCT01915667
Drug: 200 mg GLPG0634 as tablets, fasted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
Trial: NCT01915667
Drug: 200 mg GLPG0634 as tablets, fed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose of 200 mg GLPG0634 given as tablets in fed condition
Trial: NCT02350686
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
Trial: NCT00687297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03829618
Drug: Nebuliser Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine dosed at 2 mg/kg (max 160 mg) applied via vibrating mesh nebulizer
Trial: NCT00893009
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg twice a day
Trial: NCT00893009
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03711279
Drug: ADM plus IFO or IFO alone
RxNorm normalized name: Sooth-It Plus Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used.
Trial: NCT01913431
Drug: Baracle Tab.®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01913431
Drug: Baraclude Tab.®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04303026
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5mg IV infusion
Trial: NCT04303026
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Group. Saline 0.9% 100 ml infusion
Trial: NCT00405522
Drug: Propofol 2.0 mg/kg + Remifentanil 1.5 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
Trial: NCT00405522
Drug: Propofol 4.0 mg/kg + Remifentanil 0.5 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
Trial: NCT03740555
Drug: HNC042 single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HNC042,freeze-dried powder,single ascending doses Single dose, Intravenous route,starting dose of 100mg escalating up to 1200mg
Trial: NCT03740555
Drug: Placebo multiple ascending doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, multiple ascending doses, Intravenous route, Multiple doses, daily for 7 days, matching placebo
Trial: NCT03937440
Drug: Deep neuromuscular block with 'rocunium®'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for post-tetanic count (PTC) in deep neuromuscular group.
Trial: NCT03937440
Drug: Moderate neuromuscular block with 'rocunium®'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium will be maintained in a arm 1) deep neuromuscular block group or arm 2) moderate neuromuscular block group (control group) according to the assignment. The degree of muscle relaxation is determined by 1 to 2 for train-of-four (TOF) in moderate neuromuscular group.
Trial: NCT01866657
Drug: Vasoconstrictor Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
Trial: NCT01866657
Drug: Additional anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
Trial: NCT01866657
Drug: Increase FiO2
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase FiO2 to improve oxygen delivery to tissue
Trial: NCT01421186
Drug: MOR03087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOR03087 will be administered according to the Maximum Tolerated Dose (MTD) or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
Trial: NCT02126267
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin (500 mg) once daily for 3 consecutive days.
Trial: NCT02939742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Trial: NCT00978250
Drug: 5-Fluoro-2'-Deoxycytidine (FdCyd) + Tetrahydrouridine (THU)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the area under the curve (AUC) of the parent compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into deoxyribonucleic acid (DNA) and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNMT, and in turn DNA methylation, can result in the re-expression of tumor suppressor genes.